RCEL reports Q1 2026 revenue of $19.3 million, up 4% year-over-year, as reimbursement stability supports full-year guidance.
AVITA Medical (RCEL) maintained its 2026 revenue guidance of $80 million to $85 million, citing improved reimbursement consistency for its RECELL system. The company reported Q1 2026 revenue of $19.3 million, a 4% year-over-year increase and 10% sequential growth.
Management attributed the stabilization to operational adjustments and early signs of normalized performance. The guidance reaffirmation follows a period of variability in reimbursement processes, which had previously impacted revenue trends.
No immediate market reaction was detailed in the earnings call insights.